Israel L, Melac M, Milinkevitch D, Dubos G
Grenoble University Hospital, France.
Int Psychogeriatr. 1994 Fall;6(2):155-70. doi: 10.1017/s1041610294001729.
A double-blind randomized trial was performed involving 162 patients with age-associated memory impairment (AAMI) selected and followed by their general practitioners. Two intervention methods--a drug and a cognitive therapy--were assessed in combination. Three randomized parallel groups of 54 patients each, aged 55 years and over, were followed and treated for 3 months. After a placebo wash-out period of 10 days, one group received 2.4 g of piracetam, another group, 4.8g, and the third, a placebo. A total of 135 patients, 45 in each group, completed the study. Combined therapy was most effective in patients whose baseline performance on memory tests was lowest. The best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment. This result was confirmed by the global impression of the principal investigator.
一项双盲随机试验对162名由全科医生挑选并跟踪的年龄相关性记忆损害(AAMI)患者进行。对两种干预方法——一种药物和一种认知疗法——进行了联合评估。将年龄在55岁及以上的患者随机分为三个平行组,每组54人,随访并治疗3个月。在10天的安慰剂洗脱期后,一组接受2.4克吡拉西坦,另一组接受4.8克,第三组接受安慰剂。共有135名患者(每组45名)完成了研究。联合疗法对记忆测试基线表现最低的患者最有效。服用4.8克吡拉西坦时观察到最佳效果,尤其是在药物治疗6周后开始训练课程时。这一结果得到了主要研究者的整体印象的证实。